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INTRODUCTION
Cardiovascular Diseases (CVD) are the most frequent cause of morbidity and the leading cause of 
death in western societies and worldwide; furthermore, it remain today a great social and public  
sanity problem in Italy, due to the high number of people suffering these pathologies and the need  
for longterm care and rehabilitation trials (Braunwald E. 1997). CVD includes heart and blood 
vessel disease and their pathogenesis is related to atherosclerosis. Atherosclerosis is a condition 
that develops when a substance called plaque builds up in the walls of the arteries. This buildup 
narrows the arteries, making it harder for blood to flow through. If a blood clot forms, it can stop  
the blood flow and induce to heart attack or stroke.
The  atherosclerosis  leads  to  the  development  of  atherosclerotic  disease,  the  most  frequent 
cardiovascular pathology, and its manifestations, in particular ischemic disease (acute myocardial 
infarction  (AMI)  and  angina  pectoris)  and  cerebral  disease  (ischemic  ictus  and  hemorrhagic 
ictus). 
A heart attack or AMI occurs when the blood flow to a part of the heart is blocked by a blood clot.  
If this clot cuts off the blood flow completely, the part of the heart muscle supplied by that artery 
begins to die. Usually, this is because one of the coronary arteries that supplies blood to the heart 
develops a blockage due to an unstable buildup of white blood cells, cholesterol and fat. The  
event is called "acute" when it is sudden and serious. The two main ways to determine if a person  
had AMI are electrocardiograms (ECGs) that trace the electrical signals in the heart and testing 
the blood for substances associated with damage to the heart muscle. Common blood tests are 
creatine kinase (CK-MB) and troponin. ECG testing is used to differentiate between two types of 
AMI based on the shape of the tracing. When the ST section of the tracing is higher than the  
baseline  it  is  called  an  ST-elevation  AMI  (STEMI)  which  usually  requires  more  aggressive 
treatment. Usually, when an event occurs in young age (35-45 years), the AMI is often fatal. In  
advanced age, often, the survivors to an AMI become a chronic patient that need continuous care 
all life long with high cost for society. Furthermore, the CVD are strongly associated to ageing 
and conduce to physically and cerebrally impairment.
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An ischemic stroke happens when a blood vessel that feeds the brain gets blocked, usually, from a 
blood clot.  When the blood supply to  a part  of  the  brain is  shut  off,  brain cells  will  die.  A 
hemorrhagic stroke occurs when a blood vessel within the brain bursts. The most likely cause is  
uncontrolled hypertension.  The result  will  be  the  inability to  carry out  some of  the  previous 
functions as before like walking or talking. Some effects of stroke are permanent if too many 
brain cells die after a stroke due to lack of blood and oxygen to the brain. These cells are never 
replaced; others are only temporarily out of order.
Other types of CVD are: 1) Heart failure: means the heart is not pumping blood as well as it 
should, but  the  body's  need  for  blood  and  oxygen  is  unchanged; 2)  Arrhythmia:  this  is  an 
abnormal rhythm of the heart that can beat too slow, too fast or irregularly, so the heart may not  
be able to pump enough blood to meet the body's needs; 3)Heart valve alterations: when heart 
valves do not open enough to allow the blood to flow through as it should two main alteration are  
observed valve stenosis and insufficiency.
Epidemiology
CVD kill  an estimated 17 million people  worldwide each year  and over  4 million deaths  in 
Europe.  CVD  weigh  for  59%  on  global  mortality  versus  27%  of  tumor  (World  Health 
Organization.  The  top  10  causes  of  death,  factsheet  No.  310.  Retrieved  14  August  2013 
http://who.int/mediacentre/factsheets/fs310/en/index.html).  CVD  costs  the  Europe  economy 
almost 196bn of euros per year (European Cardiovascular Disease Statistics 2012 Edition, p116. 
Retrieved 14 August 2013. http://www.escardio.org/about/Documents/EU-cardiovascular-disease-
statistics-2012).In Italy, CVD are the most frequent cause of dead and AMI is the main clinical 
complication of CVD.
In our country, the last data regarding the epidemiology of CVD come from  Istat and  Istituto 
Superiore di Sanità (ISS) in 2008. CVD cause 224.482 death per year (38,8% of total death). Of 
these, 33% are cardiovascular event (CVE) (AMI, ischemic heart diseases, angina pectoris and 
other chronic form of ischemic heart diseases).
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Classical risk factors
The  knowledge  of  the  etiology  and  pathogenetic  mechanisms  of  CVD  is  still  limited  and 
incomplete. Well-known traditional risk factors include associated with CVD are: 
Age: the risk of developing CVD increases between 40-50 years for men and 50-60 for women;  
Gender: the women are protected by sexual hormones up to the menopause and thereafter the 
percentage  of  CVE  between  women  will  increase.  Therefore,  gender  is  another  important  
classical risk factor. 
A family history of early heart disease: heart disease diagnosed before age 55 years in the father  
or a brother and before age 65 years in the mother or a sister  increases the risk of CVD in 
offspring and sibling.
Race: African Americans are reported to be particularly at high risk to develop CVD than Asians, 
perhaps for the high levels of low-density lipoprotein cholesterol (LDL-C). The increased risk 
may  be  also  associated  with  the  different  diets.  Age,  gender,  race  and  familiarity  are  not-
modifiable risk factors. 
High cholesterol level: the Framingham Heart Study demonstrated that specially LDL-C, was the 
greater the risk of CVD. In 1984, the Lipid Research Clinics-Coronary Primary Prevention Trial 
revealed that lowering total and LDL (bad cholesterol levels) significantly reduced coronary heart 
disease (CAD). CAD was uncommon in people with cholesterol levels below 150 mg/dL. More 
recent series of clinical trials using statin drugs provided conclusive evidence that lowering LDL 
cholesterol  reduces the rate of AMI, the need for percutaneous coronary intervention and the 
mortality associated with CAD-related causes (LaRosa JC et al., 2005)
Hypertension: in the Framingham Heart Study, even high-normal blood pressure (defined as a  
systolic blood pressure of 130-139 mm Hg, diastolic blood pressure of 85-89 mm Hg, or both)  
increased the risk of CVD 2-fold, as compared with healthy individuals (Vasan RS et al., 2001). A 
study by Allen et al. found that people who have increased or decreased in blood pressure during 
middle age had higher and lower remaining lifetime risk for CVD. This suggests that prevention 
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efforts should continue to emphasize the importance of lowering blood pressure in order to avoid 
hypertension  (Allen  N et  al.,  2012).  Hypertension,  along  with  other  factors  such  as  obesity 
contribute  to  the  development  of  left  ventricular  hypertrophy (LVH).  LVH founded to be an 
independent  risk  factor  to  CVD  morbidity  and  mortality.  It  roughly  doubles  the  risk  of 
cardiovascular death in both men and women (Levy D et al., 1990).
Obesity: the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure (JNC VII) emphasizes weight control, adoption of the Dietary Approaches 
to Stop Hypertension (DASH) diet, with sodium restriction and increased intake of potassium and 
calcium-rich food, moderation of alcohol consumption to less than 2 drinks daily and increased 
physical activity (Chobanian AV et al., 2003). Obesity was associated with elevated vascular risk 
in population studies. In addition, this condition was associated with glucose intolerance, insulin 
resistance, hypertension, physical inactivity, and dyslipidemia (Rexrode KM et al., 1998). A study 
by Das et al examined more than 50,000 patients from the National Cardiovascular Data Registry 
with STEMI. The results suggested that although patients who were extremely obese (body mass 
index [BMI] >40) present at a younger age with STEMI, they have less extensive CAD and better 
LV function. However, as expected, their in-hospital mortality following STEMI was increased 
(adjusted odds ratio, 1.64) (Das SR et al., 2011).
Diabetes Mellitus: a disorder of metabolism associated with either insulin deficiency or insulin 
resistance. Glucose builds up in the blood stream, overflows through the kidneys into the urine, 
and results in the body losing its main source of energy, even though the blood contains large 
amounts of glucose. Patients with diabetes are 2-8 times more likely to experience future CVE 
than age-matched and ethnically matched individuals without diabetes (Howard BV et al., 2002).  
A recent study suggested a potential reduction of all-cause and CVD mortality in women with 
diabetes  mellitus  who  consumed  whole-grain  and  bran  (He  M  et  al.,  2010).  Another  study 
suggested  that  meat  consumption  was  associated  with  a  higher  incidence  of  coronary  heart  
disease and diabetes mellitus (Micha R et al., 2010). A meta-analysis performed by Nordmann et  
al founded that the Mediterranean diet had more favorable changes in weighted mean differences 
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of body weight, body mass index, systolic blood pressure, diastolic blood pressure, fasting plasma 
glucose, total cholesterol, and high-sensitivity C-reactive protein than low-fat diets (Nordmann 
AJ et al., 2011).
Sigarettes  smoking:  Cessation  of  cigarette  smoking  constitutes  the  single  most  important 
preventive measure for CAD. As early as the 1950s, studies reported a strong association between 
cigarette smoke exposure and heart disease. Persons who consume more than 20 cigarettes daily 
have a 2- to 3-fold increase in total heart disease. Continued smoking is a major risk factor for 
recurrent heart attacks (Rea TD et al., 2002). Smoking is a risk factor for CVD in women and 
men; however, a systematic review and meta-analysis by Huxley and Woodward suggested that in 
some countries, smoking by women is on the rise; the study suggested that proper counseling and 
nicotine addiction programs should focus on young women (Huxley RR et al., 2011).
Physically exercise:  The cardioprotective benefits of  exercise include reducing adipose tissue,  
which decreases obesity; lowering blood pressure, lipids, and vascular inflammation; improving 
endothelial  dysfunction,  improving  insulin  sensitivity,  and  improving  endogenous  fibrinolysis 
(Thompson PD et al., 2003). In addition, regular exercise reduces myocardial oxygen demand and 
increases exercise capacity, translating into reduced coronary risk. Studies shown that even 15 
minutes a day or 90 minutes a week of moderate-intensity exercise may be beneficial (Greenland 
P et al., 2010).
Modifiable risk factors are cigarettes smoke, diabetes, hypertension, hypercholesterolemia, high 
Body Mass Index (BMI), obesity, sedentary life-style changing the diet and follow a good life-
style habit. Many sanitary preventative interventions of ISS to promote the good life style, to stop 
smoking, improve physically activities, and eat better (few salt, fat, or sweet) have decreased the 
incidence of CVD, in fact, in the last 40 years the mortality for CVD it’s the half.
It was observed that more than half of patients with atherosclerotic complications, such as AMI,  
does not demonstrate classical risk factors.
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New risk factors
Others factors are now considered as new risk factors (Ridker PM, 1999, Rifai et al, 2001). 
C-reactive  protein  (CRP):  is  a  protein  in  the  blood  that  demonstrates  the  presence  of 
inflammation, which is the body's response to injury or infection; CRP levels rise if inflammation 
is present. The inflammation process appears to contribute to the growth of arterial plaque, and in 
fact, inflammation characterizes all phases of atherothrombosis and is actively involved in plaque 
formation and rupture. According to some research results,  high blood levels of CRP may be 
associated with an increased risk of developing CAD, CVE and having a heart attack (Arroyo-
Espliguero R et al., 2004; Rifai N et al., 2001). In the Jupiter trial, in healthy persons without 
hyperlipidemia  but  with  elevated  high-sensitivity  CRP  levels,  the  statin  drug  rosuvastatin 
significantly  reduced  the  incidence  of  major  CVE  (Ridker  PM  et  al.,  2008).  The  2010 
ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults states that 
measurement of CRP can be useful in selecting patients for statin therapy and may be reasonable  
for  cardiovascular  risk  assessment,  depending  on  the  patient’s  age  and  risk  level.  CRP 
measurement is not recommended for cardiovascular risk assessment in asymptomatic high-risk 
adults, low-risk men 50 years or younger, or low-risk women 60 years or younger (Wang TJ et al., 
2006).
An  elevated  lipoprotein(a)  [Lp(a)]  level  is  an  independent  risk  factor  of  premature  CAD 
(Hjemdahl  P,  2002;  Braunwald  E,  1997)  and  is  a  significant  risk  factor  for  premature 
atherothrombosis and CVE. Measurement of Lp(a) is more useful for young individuals with a 
personal or family history of premature vascular disease and repeat coronary interventions. The 
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults states 
that, in asymptomatic intermediate-risk adults, lipoprotein-associated phospholipase A2 might be 
reasonable for cardiovascular risk assessment (TJ et al., 2006). Lp(a) may be used to identify 
people  at  increased  cardiovascular  risk,  but  as  of  yet,  there  have  been  no  studies  on  Lp(a) 
lowering  because  of  the  lack  of  available  agents  that  are  effective  in  reducing  this  value. 
Therefore,  LDL lowering  is  probably the  best  strategy in  people  with  elevated Lp(a)  levels.  
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(Arrojo et al., 2004).
Homocysteine:  a  natural  by-product  of  the  dietary breakdown  of  protein  methionine.  In  the 
general population, mild to moderate elevations are due to insufficient dietary intake of folic acid.  
Homocysteine levels may identify people at increased risk of heart disease, but again, due to the 
lack of agents that effectively alter the homocysteine levels, studies have not shown any benefit 
from lowering the homocysteine level (Miller, A et al., 1997). Levels of fibrinogen: an acute-
phase reactant,  increase during an inflammatory response.  This soluble protein is involved in 
platelet  aggregation  and  blood  viscosity,  and  it  mediates  the  final  step  in  clot  formation.  
Significant associations were found between fibrinogen level and risk of CVE in the Gothenburg, 
Northwick Park, and Framingham heart studies (Wilhelmsen L et al., 1984;  Levenson, J., et al., 
1995).
Low serum testosterone levels have a significant negative impact on patients with CAD. More  
studies  are  needed  to  assess  better  treatment  (Malkin  CJ  et  al.,  2010).  One  meta-analysis 
suggested that the presence of erectile dysfunction increases the risk of CVD, coronary heart 
disease, stroke, and all-cause mortality. This additional risk may be independent of conventional  
cardiovascular risk factors (Dong JYet al., 2011).
One study suggested that women aged 50 years or younger who undergo a hysterectomy were at 
an increased risk for CVD later in life (Ingelsson E et al., 2011). Oopherectomy also increases the  
risk for both coronary heart disease and stroke.
A prospective cohort study (n=2312) by Kestenbaum et al evaluated older patients without CAD 
over 14 years. Vitamin D and parathyroid hormone were measured and the outcomes included 
AMI,  heart  failure,  cardiovascular  death,  and  all-cause  mortality.  Vitamin  D  deficiency was 
associated with increased mortality and AMI (each 10 ng/mL drop in vitamin D was associated 
with 9% greater increase in death and 25% increase in AMI). Parathyroid hormone excess was  
associated with a 30% increased risk of heart failure. Further randomized controlled trials are 
required (Kestenbaum B et al., 2011).
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Inflammation
Inflammation  appears  to  be  important  in  the  pathogenesis  of  atherosclerotic  disease,  since 
atherosclerotic plaques and lesions are associated with infiltration of activated immune cells and 
increased expression and synthesis of inflammatory markers (Hansson GK. 2001). 
Cytokines  are  produced  in  a  variety of  tissues  and  regulate  the  expression  of  a  number  of  
inflammatory molecules, leading to destabilization and finally rupture of vulnerable atheromatic 
plaques.  They also participate  in  the  pathophysiology of acute coronary syndromes by direct 
effects on myocardial contractility and apoptosis. Several lines of evidence indicate that increased 
inflammatory cytokine levels and inflammatory cytokine activity detectable in peripheral blood 
have a  prognostic  role  since they are  useful  markers  predicting future  CVE in patients  with  
advanced  atherosclerosis  and  in  patients  after  coronary  syndromes  and  may  be  useful  in 
identifying subjects with a worse clinical course (Tousoulis D et al., 2006; De Gennaro L et al., 
2012).
However, the existing data are limited and controversial. Potentially thousands of molecules are 
relevant to this apparently complex disease. Research paid much attention to sensitive specific  
serum biomarkers for vulnerable plaques as diagnostic tools for the identification of patients with 
acute coronary syndrome, but also to help us to identify high-risk patients. Furthermore, AMI is a 
myocardial necrosis occurring due to persistent coronary ischemia, in which inflammation plays 
an important role and heart failure is a common complication.
Elevated plasma levels of interleukine (IL-) 6 associated with increased risk of future AMI in a  
prospective  study that  involving 14916 apparently healthy men  were found.  These data  thus 
support a role for cytokine-mediated inflammation in the early stages of atherogenesis (Ridker 
PM et al., 2000). IL-6 plasma levels was also associated with increased atherosclerosis when the 
control group was compared with the group free of subclinical CVD (Jenny, N.S et al., 2002).      
IL-6 levels differentiated those with subclinical CVD from those without. Although the -174C 
allele was not associated with incident events, associations of the genotype with inflammation 
and AMI, combined with the plasma IL-6 results, suggest that IL-6 may chronically predispose an 
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individual to develop atherosclerosis.
Chiappelli et al. suggested that the C allele of the promoter polymorphism in the IL-6 gene is a  
risk factor for AMI in the elderly and the production of the IL-6 differentially affected different 
genotypes of the IL-6 −174 promoter polymorphism (Chiappelli M et al., 2005).
Elevated admission level of IL-6, but not of soluble CD40 ligand (sCD40L), metalloproteinase- 9 
(MMP-9),  or  tissue  inhibitor  of  metalloproteinase-1  (TIMP-1),  might  indicate  the  onset  of 
STEMI, and could provide prognostic value for future cardiac mortality within 2 y in patients  
with STEMI (Tan J et al., 2008).
A significant increase in IL-6 serum level as well as a significant decrease in IL-1 receptor alpha  
(Ra)  for  patients  with  a  history of  AMI was  found.  A trend toward  higher  concentration  of 
inflammatory mediators was noticed in relation to the increase in severity of the aortic valve 
disease.  An  "inflammatory pattern"  was  associated  with  aortic  sclerosis  pathology and  these 
results suggested the persistence of a chronic inflammation in patients who experienced acute 
coronary events (Rugina M et al., 2007).
The frequencies  of  genetic  apo E (APOE) isoforms E2,  E3 and E4 were determined in 523 
patients with AMI. Significant difference in the frequency of APOE4 but not in the frequencies of 
isoforms E3 and E2 between patients and controls were observed (Utermann G et al., 1984).  
Several studies confirmed these results (Bennet AM et al., 2007).
Admission levels of serum MMP-9 and TIMP-1 closely correlated with left ventricular structure 
and function, which may be involved in the process of post-infarction remodeling of myocardium 
in AMI (Tan J et al., 2012). 
Tumor Necrosis Factor alpha (TNF-α) may be an early marker of myocardial damage because of 
the early increase of its level after ischemic injury instead of being late consequence of extensive 
tissue necrosis. A significant increase was still seen at 48 hours post admission in patients with  
signs  of  heart  failure  but  not  in  those  without  signs  of  heart  failure.  A significant  positive  
correlation was found between plasma TNF-alpha level and calcium-dependent protein kinases 
level at admission. TNF-α level may be also an important indicator of the severity of AMI and the  
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occurrence  of  heart  failure  (Fahim  MR  et  al.,  2004). Plasma  concentrations  of  TNF-α  are 
persistently elevated among post-AMI patients at increased risk for recurrent coronary events. 
These data support  the hypothesis that  a persistent  inflammatory instability is present  among 
stable patients at increased vascular risk (Ridker PM et al., 2000a).
Monocyte chemotactic protein-1 (MCP-1) appears to play a critical  role at multiple stages in 
atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and 
remodeling  after  myocardial  infarction.  In  a  large  cohort  of  patients  with  acute  coronary 
syndromes, an elevated baseline level of MCP-1 was associated both with traditional risk factors  
for atherosclerosis as well as an increased risk for death or AMI. For this reason, it is appears to  
play a crucial role at multiple stages of atherosclerosis (De Lemos JA et al., 2003 ).
Between the pro- and anti-inflammatory components of the immune system there is a dynamic 
balance, but it is know that violation of which is an important mechanism of development of  
many  pathological  states,  in  this  case,  cardiac  insufficiency. In  the  acute  phase  of  AMI, 
inflammatory activation is enhanced with predominant proinflammatory response. In the course 
of the healing process within 6 months inflammation is suppressed and the balance between pro- 
and anti-inflammatory activation is restored. The size of AMI, BMI, lipid levels and the baseline  
levels of inflammatory markers influence the levels of inflammatory factors (Karpiński Ł et al., 
2009).
Balance between the pro-  and antiinflammatory cytokines  reflects  the  index of  inflammatory 
activity. A study demostrated that uncomplicated AMI patients, there is initially a high level of 
both proinflammatory and antiinflammatory cytokines. After 10 days, were observed a decline in 
the IL-6 level and an increase in the TNF-α and IL-10 levels. In complicated AMI, as compared 
to  uncomplicated  AMI  patients  were  observed  initially  high  levels  of  TNF-α  and  IL-6  and 
reduced levels of IL-8 and 1L-10,  patients.  In dynamics of supervision of this  group,  further 
increase of all proinflammatory cytokines and a decline of IL-10 was registered (Havrylenko TI 
et al., 2012).
Soluble interleukin (IL)-2 receptor (sIL-2r), IL-6, and IL-8 are increased in patients with acute 
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coronary syndrome and systolic dysfunction or acute heart failure (De Gennaro L et al., 2012).  
Some findings suggested that  IL-8 and IL-12 was involved in  the  process  of  ischemic heart 
disease, and serum IL-12 may be a marker for differentiating AMI from unstable angina pectoris  
(Zhou  RH  et  al.,  2001).  A  number  of  studies  associated  blood  levels  of  individual 
proinflammatory plasma biomarkers and gene variants  that  favor inflammation or  cholesterol 
synthesis with AMI, but until now, none of these factors alone are sufficient to define risk for 
individuals. Furthermore, phenotype markers, blood levels of a given marker, may considerably 
vary with gender, age, concomitant diseases, metabolic disorders and diet, be sensitive to other 
environmental variables and significantly change with time in the same subject.
Genetic risk factors
Plasma levels of lipids and proinflammatory molecules fluctuate over time and in relation to age,  
sex, diet, lifestyle, medication, and environmental factors, limiting their usefulness in etiologic 
and predictive contexts. Inherited gene variants are, in contrast, constant and might provide a 
better  indication  of  high  intrinsic  risk.  Genetic  markers  may  be  used  to  overcome  these 
limitations.  For  instance,  gene  polymorphisms  (SNPs),  known  to  influence  the  phenotypic 
expression of a given inflammatory molecule, may become informative in assessing individual 
risk  of  CVE  and  recent  studies  have  focused  on  the  genetic  background  of  inflammatory 
cytokines as possible intrinsic risk factors associated with CVD. These investigations assessed 
gene variations largely distribute in human population and showed that some alleles of cytokine 
genes were more frequently distributed in patients with CVD than in controls (Humphries SE et 
al., 2001; Andreotti F et al., 2002). 
Cytokines  as  regulators  of  activity  of  inflammation  play  significant  role  in  mechanisms  of 
formation of  atherosclerotic plaques and in processes of their  destabilization.  One of leading  
genetic factors determining level of their production appears to be polymorphism of cytokine 
genes structure at their promoter loci (Konenkov VI et al., 2012).
Recent genome-wide association (GWA) studies have contributed substantially to the discovery 
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of new SNPs associated with CHD and AMI (Patel RS et al., 2011), but their clinical relevance is 
still unclear because a single gene variant can make a limited contribution to the total genetic load 
of AMI, and both common and rare gene polymorphisms may differentially affect susceptibility 
to the disease.
Data from a cross-sectional study suggested that the functional  interaction of three genes the  
allele C of IL-1b, the allele C of IL-6 and e4 allele of APOE was strongly associated with AMI, 
affects pathogenetic mechanisms and an impaired regulation of immune responses plays a pivotal 
role in the disease (Licastro F et al., 2004). In the setting of non-ST-elevation acute coronary 
syndromes, genetic variation at the IL-1 gene locus contributes to the changes in soluble markers  
of endothelial inflammation (Ray KK et al., 2002). 
A number  of  studies  explored  the  association  of  ischaemic  heart  disease  with  SNPs  of  the 
inflammatory molecules TNF-α and β, transforming growth factors (TGF) beta1 and 2, IL-1 and 
its receptor antagonist (IL-1ra), the receptor for lipopolysaccharide (CD14), P and E selectins, and 
platelet endothelial cell adhesion molecule (PECAM) 1. The data provided some evidence that 
alterations in the genetics of the inflammatory system may modify the risk of ischaemic heart 
disease (Andreotti F et al., 2002).
Several  gene variants  that  promote inflammation and cholesterol  metabolism were associated 
with  AMI.  Promoter  SNPs  with  functional  relevance  in  the  expression  of  the  cognate 
inflammatory gene are often found at elevated frequency among patients with AMI. AMI across a 
broad  age  range’  carried  multiple  proinflammatory  alleles  (IL6,  TNF,  IL10,  Alpha  1-
antichymotrypsin  (ACT)).  ‘A subset  of  AMI  in  middle  age’ had  numerous  proinflammatory 
alleles  (IL6,  TNF, ACT,  interferon gamma IFN-γ,  3-hydroxy-3-methyl-glutaryl-CoA reductase 
(HMGCR)). ‘AMI after age 80’ had a reduced risk set (IL6, IL10, IFN-γ) (Licastro F et al., 2011; 
Licastro F et al., 2007).
IL-10  reflects  a  proinflammatory  state  in  patients  with  acute  coronary  syndrome  and  was 
suggested that IL-10 is as effective a biomarker for the risk prediction of future CVE as other 
markers of systemic inflammation (Mälarstig A et al., 2008). Also IL-8 -251 A/T polymorphism is 
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associated with acute coronary syndrome risk in the Chinese Han population and the A allele of  
IL-8 -251 A/T may be an independent predictive factor for acute coronary syndrome (Zhang X et  
al.,  2011). IL-18 gene is  a susceptibility locus for AMI, a finding of potential  interest  in the  
clinical practice (Koch W et al., 2011a).
Six different and functionally relevant SNPs of the genes coding for IL-10, TNF-α, and TNF-β 
are  neither  separately  nor  in  cooperation  associated  with  the  risk  of  CAD  or  AMI  in 
angiographically examined study patients (Koch W et  al.,  2001b).  Also a relationship among 
genetically determined TNF-α and pro-thrombin (FII) production and increased levels of tissue 
damage  markers  of  AMI,  suggest  that  a  complex  genetic  background,  might  be  involved in 
susceptibility  to  AMI  in  young  men  influencing  the  extension  and  severity  of  the  disease 
(Vaccarino L et al., 2013).
Although many risk factors are intercorrelated, raising the possibility of a higher level of genetic 
control by a small number of master genes that control fundamental physiological systems. Such 
genes  are  likely to  be relevant  to  the  combined processes  of  plaque instability and coronary 
thrombosis.
The  complex  pathogenesis  of  AMI  implicates  phenotypic  and  genetic  heterogeneity.  A new 
mathematical algorithm named Auto Contractive Map (AutoCM), was applied in AMI patients to 
detect and evaluate the relationships among genetic factors, clinical variables and classical risk 
factors. Genes were selected because their strong regulatory effect on inflammation and SNP in 
these gene were located in the promoter region. In the connectivity map generated by AutoCM a 
group of variables was directly linked with the AMI status: gender (male), early age at onset (50-
65 years), HMGCR gene (CC wild type genotype), IL-1β, ACT, IL-6 GG and vascular endothelial 
growth  factor  (VEGF)  CC  genotypes.  This  direct  link  suggested  a  possible  pathogenetic 
association with AMI. Other genetic,  clinical and phenotypic variables were associated to the 
disease under a statistically defined hierarchy showed in the new connectivity map generated by 
AutoCM. These analyses suggested also that genotypes of few inflammatory genes, a SNP in 
HMGCR gene, middle age, gender, low HDL and diabetes were very informative variables to 
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predict the risk of AMI (Licastro F et al., 2010).
Familiarity of CVD
Parental history is a widely accepted risk factor for offspring CVE, although the mechanisms 
remain unclear. Many studies examined the contribution of conventional and genetic risk factors 
in explaining the excess risk of CVE in offspring with positive parental history.  Whether parental 
CVD confers increased risk independent of other risk factors remains controversial. Prior studies 
relied on offspring report, without complete validation of parental events.
Despite some study underline an association of positive parental history with blood pressure, total 
and high-density lipoprotein cholesterol, CRP, and physical activity, less than 15% of the risk was 
explained through conventional and novel risk factors. The greatest risk of CVD was observed in 
positive  parental  history  participants  with  elevated  CRP  or  hypertension  and  substantially 
increases the risk of CVD (Hamer M et al., 2009). 
Genotypes  of  inflammatory  molecules  seem to  play  an  opposite  role  in  atherosclerosis  and 
longevity: pro-inflammatory genotype seems to contribute significantly to the risk of coronary 
heart  disease,  but  some study supported the hypothesis  that  the  genetic  background favoring 
CVD. So several study in centenarian verify the role of proinflammatory alleles, such as pyrin  
and C-C chemokine receptor type 5 (CCR5), in AMI and longevity. The results suggested the 
genetic background favoring CVD and that the centenarian genetic background may be useful for  
investigating genetic key components of age-associated diseases as atherosclerosis (Candore G, et  
al., 2006).
A family history of CVD and AMI is frequently encountered in clinical practice, and a premature 
heart attack in parents is associated with a high risk of the disease in their offspring. A small  
subgroup of children, whose parents suffered a heart attack in their late thirties and early forties,  
may be  at  particularly high  cardiovascular  risk  was  evaluated  about  weight,  blood  pressure, 
plasma cholesterol levels, obesity and smoking and it is concluded that cardiovascular risk factor 
screening  among  children  with  a  positive  family  history  of  premature  atherosclerotic 
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complications is appropriate and cost-effective (Rumboldt M et al., 2003).
To assess the risk of CVE, the diagnostic effectiveness of molecular-genetic markers (SNPs in 
APOE, ACE (I/D) and MTHFR (C677T) genes) in combination with conventional risk factors 
was  studied.  The  combination  of  results  of  molecular-genetic  testing  with  conventional  risk 
factors allows to increase the predictability of cardiovascular risks (Nazarenko GI et al., 2009).
Some study examined the association of parental CVD with 8-year risk of offspring CVD, using 
pooled logistic regression.  Parental  CVD independently can predict  future offspring events in 
middle-aged  adults.  Addition  of  parental  information  may  help  clinicians  and  patients  with 
primary prevention of CVD, when treatment decisions may be difficult in patients at intermediate 
risk based on levels of single or multiple risk factors (Lloyd-Jones DM et al., 2004). 
The relevance of familial factors to CVD is further supported by the finding that siblings with 
CVD are at increased risk of future CVE in middle-aged adults regardless of the presence of 
established risk factors (Murabito JM et al., 2005).
The associations of parental longevity with carotid intima-media thickness, carotid plaques, and 
aortic arterial stiffness in adult offspring was also examined and the results indicate that there are 
modifications of structure and function of large arteries according to paternal longevity (Zureik M 
et al., 2006). 
Data  from the longitudinal  Framingham Heart  Study confirmed that  subjects  with long-lived 
parents have a better cardiovascular risk profile in middle age than those whose parents died 
younger and centenarians have better cardiovascular risk profiles compared to younger old people 
(Terry DF et al., 2007).
Some reports revealed that CVD (i.e. hypertension, diabetes, angina and/or myocardial infarction) 
are less common in centenarians respect to 70 and 80 years old persons. A combination of genetic 
factors and lifestyle aspects appears to contribute to the longevity of centenarians. A role on this 
better  cardiovascular  risk  profile  may  be  played  by  the  increasing  use  of  pharmacologic 
treatments  in  the  elderly  population  (especially  for  hypertension  and  dyslipidemia),  but  the 
contribution  of  drug  treatments  to  promote  extreme  longevity  is  not  confirmed.  In  fact, 
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centenarians in  general  needed  fewer  drugs  at  younger  ages  due  to  a  healthy lifestyle.  The 
importance  of  the  genetic  contribution  was  demonstrated  by  the  inheritance  of  low-risk 
cardiovascular profiles in centenarian offspring and lower prevalence of cardiovascular CVD in 
this population as compared with their spouses or with age-matched subjects without centenarian 
parents (Galioto A et al., 2008). 
Furthermore, the Offs of centenarians have a better cardiovascular risk profile and retain some 
important  cardiovascular advantages over time than those of parents not  enjoying a long life 
(Adams ER et al., 2008). It is interesting to note that structural vascular changes can be observed  
in Offs with a parental history of AMI at a young age, regardless of the presence of a number of  
the  classical  cardiovascular  risk  factors.  Increased  carotid  intima-media  thickness  is  an  early 
manifestation of atherosclerosis.  A parental history of premature AMI was associated with an  
increase  in  carotid  carotid  intima-media  thickness  in  children-adolescents  and  young  adults. 
Offspring  of  coronary  patients  showed  an  unfavourable  lipid  profile  compared  to  controls;  
however,  the  association  between  a  premature  AMI  and  carotid  intima-media  thickness  was 
independent of lipids, apolipoproteins and other traditional risk factors. So, vascular structural  
changes  are  detectable  in  Offs  of  parents  with  premature  AMI  at  a  young  age  and  occur 
independently of several traditional cardiovascular risk factors (Barra S et al., 2009).
Once again, the Framingham Heart Study shown that parental stroke before the age of 65 years is 
associated with a 3-fold increase in the risk of stroke in their Offs, and that parental history can be  
used as clinical risk marker of an individual’s propensity to stroke (Seshadri S et al., 2010). 
The distribution of some SNPs influencing a inflammation and found an higher prevalence of 
pro-inflammatory SNPs (SNP A2080G of pyrin gene, SNP Gly670Arg of PECAM gene, C1019T 
of Cx 37 gene, SNP G1059C of PCR gene) and a lower prevalence of anti-inflammatory SNPs 
(Asp299Gly of TLR4 gene, SNP -1082 G/A of IL10 gene, CCR5Δ32) in young patients with AMI 
was found. Results of these studies shown that early AMI could be associated with a genetic  
predisposition  to  an  intense  inflammatory  response,  also  to  an  hyperviscosity  syndrome 
(Incalcaterra E et al., 2010).
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All  these  findings  suggest  that  genetic  studies  of  offspring  may  be  useful  to  identifying 
transmissible genetic traits in CVD.
Environmental factors
Studies  about  associations  of  infections  with  viruses  and other  pathogens,  with  CVD, frailty 
and/or mortality are conflicting. Since high levels of antibodies against these pathogens occur in 
the elderly, the role of pathogens in morbidity and mortality of vulnerable elderly was explored.  
Increasing evidence supports a link between serological evidence of prior exposure to infectious  
pathogens, pathogen burden, and the risk for future AMI and death in patients with coronary 
artery  disease.  The  role  of  viral  infections  in  the  pathogenesis  of  atherosclerosis  remains  
controversial largely due to inconsistent detection of the virus in atherosclerotic lesions, but the 
identification of  specific  viral  signatures  can help to  understand pathogenetic  mechanisms in 
AMI. 
In the past, evidence for enterovirus (EV), adenovirus, and cytomegalovirus (CMV) was in the 
focus  of  attention;  in  the  meantime,  "new"  cardiotropic  pathogens  such  as  parvovirus  B19, 
Epstein-Barr  virus  (EBV),  and  human  herpesvirus  (HHV-)  6  in  patients  with  dilated 
cardiomyopathy with  and without  inflammation  have  been  detected.  Their  persistence  in  the 
myocardium correlates with a decline in pumping capability within 6 months. While the virus is 
still  being  eliminated,  the  second  phase  of  the  disease  begins,  which  is  characterized  by 
autoimmune phenomena and often a cardiac inflammatory response which likewise correlates 
with a worsening prognosis. The transition to the third and final  phase with development of 
dilated cardiomyopathy occurs gradually and can take years. The goal of every diagnostic and 
therapeutic intervention must be to eradicate the virus and eliminate the inflammatory response to 
prevent the disease from progressing to terminal cardiac insufficiency (Pankuweit S et al., 2010). 
Some  study evaluated  the  intimal  presence  of  four  pathogens  in  human  coronary atheroma, 
clinically associated with acute coronary syndromes and stable angina and the effect of pathogen 
burden  on  the  expression  of  human  heatshock  protein  60  (hHSP60),  a  key  protein  in 
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(auto-)immune pathogenesis of atherosclerosis. The data demonstrate that there exist an impact of 
intimal  pathogen  burden  in  plaque  instability,  and  suggest  the  presence  of 
(auto-)immunoreactions against upregulated hHSP60 is an important pathomechanism that may 
contribute to acute coronary syndromes (Andrié R et al., 2003).
A study assess the detection of  human HHV-6 and HHV-8, two DNA viruses with a distinct 
tropism for endothelium and lymphocytes, with the aim to know if these virus may be associated 
with  coronary  instability  and  to  found  a  correlation  between  infection-driven  inflammatory 
burden and acute manifestation of coronary artery disease. 
HHV-8 viremia was undetectable in all three groups of study: patients with AMI, patients with 
stable coronary artery disease and patients without coronary and carotid artery atherosclerosis  
subjected to cardiac valve replacement. HHV-6 viremia was detected in a substantial fraction of 
the samples examined without differences between groups (Magnoni M et al., 2012).
To  evaluate  the  association  of  ischemic  heart  disease  with  the  number  of  pathogens  among 
individuals with infection serum samples of patients with ischemic heart disease as the AMI or 
unstable angina and healthy subjects for the presence of antibodies to Helicobacter pylori (H. 
pylori), CMV, HSV-1 and HSV-2 were tested. The rate of subjects with high infection burden (3 
seropositivities) was significantly higher in ischemic heart disease group than to control group.  
The seroprevalence of anti-H. pylori, anti-CMV and anti-HSV-1 antibodies in AMI and unstable  
angina groups was significantly higher than control group. The infection burden was significantly 
increased in patients with ischemic heart disease and this parameter should be considered as an 
independent risk factor for development of ischemic heart disease (Jafarzadeh A et al., 2011).
Some study described also a dual role of infections as risk factors for coronary heart disease and 
showed that EV, HSV and Chlamydia pneumoniae (C. pneumoniae) HSP60 IgG antibody titers 
were associated with increased risk of coronary heart  disease and protection from infections,  
usually suffered during the childhood before the era of MMR vaccination, may predispose the 
individual to coronary heart disease (Pesonen E et al., 2007).
The  levels  of  IgG  antibody  specific  for  HSV-1,  CMV  and  EBV  among  patients  with 
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atherosclerotic vascular diseases were assessed to elucidate whether infectious agents such as 
herpes viruses could be implicated in the inflammatory atherosclerotic process and to examine the 
relation between the levels of these antibodies lipid profile and high-sensitive C-reactive protein 
(hsCRP) in these patients. The level of CMV- and EBV- specific antibodies were elevated among 
vascular  disease  patients  and  the  presence  of  CMV-specific  IgG  was  associated  with  the 
development  of  the  disease.  Serum  lipids  and  hsCRP  were  increased  among  the  patients; 
however, no significant correlation was detected between antiviral IgG levels and lipid profile or  
hsCRP (Al-Ghamdi A, 2012). 
The C. pneumoniae, HSV-1, CMV and EBV DNA in atherosclerotic plaques from carotid arteries 
obtained  from 17 patients  were  investigated.  Genomic  sequences  of  C.  pneumoniae,  HSV-1, 
CMV were not found in any atherosclerotic lesion. Therefore, these results did not support the 
hypothesis  of  an association between these infectious  agents  and atherosclerosis.  Conversely,  
three patients were found to be positive for EBV DNA, thus indicating that, at least in a limited 
number of patients, EBV could play a role in atherogenesis (Tremolada S et al., 2011).
The  intimal  presence  of  4  pathogens  in  atheroma,  clinically  associated  with  acute  coronary 
syndromes and stable angina and the effect on the expression of intimal CRP, tissue factor and 
hHSP60 to demonstrate the impact of pathogen burden in plaque instability and suggest local  
proinflammatory,  prothrombotic,  and  proimmunogenic  effects  was  investigated.  Analysis 
revealed C. pneumoniae was present in 73%, H. pylori in 31%, CMV in 16%, and EBV in 40%. 
Also  the  expressions  of  CRP,  tissue  factor,  and  hHSP60  were  significantly  higher  in  acute 
coronary syndromes lesions and the number of infectious pathogens correlated significant with 
the expressions of CRP, tissue factor and hHSP60 (Andrié RP et al., 2010).
In  a  cross-sectional  study,  the  presence  of  C  Pneumoniae,  Mycoplasma  pneumoniae  (M. 
pneumoniae),  CMV and EBV in atherosclerotic and non-atherosclerotic vascular samples was 
investigated. The results suggest that C. pneumoniae, M. pneumoniae and CMV were present  
with similar frequency both in atherosclerotic and non-atherosclerotic vessels (Bayram A et al., 
2011).
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The presence of HHV-6, HHV-7 and HHV-8 DNA in carotid, iliac and coronary artery specimens 
obtained from a group of subjects with atherosclerosis and a control group were investigated. 
HHV-6 but not HHV-7 and HHV-8 DNA were found in atherosclerotic vascular tissues. However, 
further research on broader study groups and with different  protocols is  needed to determine  
whether these viruses play a role in the formation of atherosclerosis (Kaklikkaya I et al., 2010). 
Explanted  heart  of  28  patients,  who  underwent  heart  transplantation  were  screened  for  EV, 
Adenovirus Type 3 (AdV3) and HHV6 sequences in order to assess the incidence of cardiac viral 
infection  that  may  be  implicated  in  the  pathogenesis  of  cardiomyopathy,  and  estimate  viral 
distribution  in  the  myocardium.  AdV3  and  HHV6  sequences  coexisted  in  one  case  with 
inflammatory cardiomyopathy (Tátrai E et al., 2011). 
The presence of CMV immediate early genomic region of DNA in 40 arterial specimens from 
coronary plaques and 27 samples from normal vessels were evaluated. CMV DNA was detected 
in 9 out of 26 patients (34.6%) in both non-atherosclerotic tissues and atherosclerotic plaques. No 
statistically significant differences were observed between normal and diseased vessels. These 
findings do not support a direct causative role of CMV in the development of atherosclerotic  
plaques (Xenaki E et al., 2009). 
Some publications shed light to the role of AdV3, HHV- 6 and EV viruses in the development of 
dilated cardiomyopathy. AdV3, HHV- 6 and EV genomes in DNA and RNA were isolated from 
five regions of the heart muscle. In 2 patients AdV3 and in 1 patient both AdV3 and HHV-6 were 
detected. The AdV3 genome was the most frequent virus genome in explanted heart tissues. The 
identified viral sequences suggested previous viral infection, which could have played a role in 
the development of dilated cardiomyopathy (Tátrai E et al., 2007).
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AIM OF STUDY
CVD are rising as a cause of death and disability worldwide and also a great social and medical  
problem and AMI is  the  main clinical  complication.  The knowledge about  the aetiology and 
pathogenetic  mechanisms  of  coronary  vessels  disease  is  limited  and  incomplete.  AMI  is  a 
multifactorial  disease  with  a  complex  pathogenesis  in  which  lifestyles,  individual  genetic 
backgrounds  and  environmental  risk  factors  contribute  to  the  pathogenetic  mechanisms  and 
clinical manifestations.
More than half of patients with atherosclerosis do not show classical risk factors. New risk factors 
for CVD are emerging as the results of a growing understanding of the process of atherogenesis. 
Inflammation  appears  to  be  important  in  the  pathogenesis  of  atherosclerotic  disease,  since 
atherosclerotic plaques and lesions are associated with infiltration of activated immune cells and 
increased expression and synthesis of inflammatory markers. Elevated blood levels of cytokines 
and interleukins in patients with CVD have been also found. However, phenotype markers, may 
considerably  vary  in  several  physiological  condition  or  be  sensitive  to  other  environmental 
variables and significantly change with time in the same subject. Genetic markers may be used to 
overcome these limitations. For instance, gene polymorphism, known to influence the phenotypic 
expression of a given inflammatory molecule, may become informative in assessing individual 
risk of CVE. 
Furthermore, it is known that a family history and a still largely undefined genetic background 
greatly influence the early clinical manifestation of AMI and CVD.
We investigated genetic variations represented by SNPs in the promoter region of a number of 
genes  regulating  metabolic  and  immune  functions  that  have  previously  been  found  to  be 
associated with an increased risk of AMI in case/control studies as possible genetic markers of an  
increased risk of CVD in children of parents with a positive history of AMI (Licastro F et al.,  
2010).
Three populations were studied: a population affect of AMI, unaffected subjects with positive 
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familiarity for  AMI and a  control  group of  patients  without  history of  CVD to improve our  
understanding about genetic background involved in the development of atherosclerosis and its 
complications. 
A second control group of comparable age from the WHO-MONICA Brianza study to compare 
CVE prevalence during the 24 years follow-up of our Offs was also used.
In second instance we investigated the same SNPs in genes in another group of AMI to confirm 
the obtained results. 
Finally, DNA samples from peripheral blood leukocytes (PBL) of all patients were analyzed for 
the presence of EBV and HHV-6 to assess the involving of a viral etiology as risk factors of CVD 
and AMI.
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MATERIALS AND METHODS
Subjects and patients
The  study involved  154  Offs  from Northern  Italy,  each  of  whom had  one  parent  who  had 
experienced an AMI before the age of 65 years. An evaluation was made of the classic AMI risk 
factors (metabolic  parameters,  smoking,  diabetes,  obesity,  a sedentary lifestyle)  together  with 
ECG records, anthropometric indices, arterial pressure and medical history. The Offs were re-
screened after a follow-up of 24 years in order to assess any changes in behavioral and biological  
risk factors and collect blood samples for laboratory and genetic evaluation. The CVD risk factors 
and drug treatments recorded at baseline and 24 years later were compared with those of the age-
matched population of the WHO-MONICA Project, which were collected in Brianza, Northern 
Italy, during independent surveys carried out in 1984, 1991 and 2004 (Ferrario M et al., 2001).
A  further  group  of  269  consecutive  patients  with  a  clinical  diagnosis  of  AMI  based  on 
electrocardiographic  changes  and  standard  laboratory  findings,  and  confirmed  by 
echocardiography and coronary angiography (Licastro F et al., 2010), who were admitted to the 
Cardiology Unit of Ferrara University Hospital during 2006–2007, was investigated. 
Another group of patients with cardiomyophaty (CMP) belonged from Cardiology Unit of Ferrara 
Hospital and included 177 AMI (patients that at the moment of  hospitalization had enzimatic 
dismission index tipical of myocardial necrosis) with two types of myocardial infarctions based 
on the shape of the tracing. An ST section of the tracing higher than the baseline is called an ST 
elevation  AMI  (STEMI)  which  usually  requires  more  aggressive  treatment  and  another  one 
without ST elevation (NSTEMI: Non ST Elevation Myocardial Infarction) (Moe KT et al., 2010). 
The  healthy  CTR  were  315  subjects  without  a  family  history  of  CVD  participating  in  the 
“Conselice study of brain aging” conducted in Northern Italy in 1999–2005 (Ravaglia G et al., 
2001), none of whom showed any signs of CVD or inflammatory diseases before or during the 
study.  The  plasma  cholesterol  and  lipid  profiles  of  the  Offs,  AMI  patients  and  CTR  were 
determined on the basis of standard laboratory procedures. The research protocol was approved 
by  our  Institutional  Review Boards,  and  all  of  the  participants  gave  their  written  informed 
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consent.
DNA estraction
5 ml of blood diluted in a Falcon with ¾ volumes of Phosphate Buffer Saline 1X  were extracted  
from the patients and were centrifuged for 20 minutes at a temperature of 4 ° C at 4000 rpm . 20 
ml of saline solution Nonidet P40/NaCl (Nonidet P40 0,1% e NaCl 0,9%)   were added to the 
pellet and it is centrifuged again for 15 minutes at 4 º C at 4000 rpm . 5 ml of lyses buffer (Urea 7 
M; NaCl 0,3 M;EDTA 10 mM; Tris-HCl 10 mM a pH 7,5) and then 1 ml of 10 % SDS were 
added to the pellet and incubated for the lysis in thermostat bath at 37 º C for 10 minutes. 7 ml of 
phenol / chloroform / isoamyl alcohol 25:24:1 were added and centrifuged for 15 minutes at 4 º C 
to 3900 rpm. the supernatant was collected it was measured the volume. 50 ml Sodium acetate is  
added to the supernatant to obtain a final concentration of 0.2 M. Then 2-3 volumes of 95% 
ethanol were added to the solution; shaking slightly,  you can see a suspension of filamentous 
DNA ( jellyfish ). The suspension was centrifuged at 4 º C at 3500 rpm for 20 minutes. To collect  
the DNA, the pellet coated into the tube was resuspended in 1 ml of 70% ethanol. The pellet thus 
collected was centrifuged at 13000 rpm for 10 minutes. Removed the ethanol, the pellet was dried 
and finally was resuspended in water by controlling the viscosity to add a quantity of water  
adequate. The concentration of DNA was read in a spectrophotometer at 260 nm . The samples 
obtained are maintained at -20 º C (Grimaldi LM et al., 2000).
SNP detection
The presence of SNPs in the promoter regions of the VEGF (−2578 C/A, rs699947), ACT (−51 
G/T, rs1884082), HMG-CR genes (−911 C/A, rs3761740), IL-1β (−511 C/T, rs16944) and IL-10 
(−1082 G/A, rs1800896) were detected by real-time PCR. The SNP-specific primers and probes 
were designed using the TaqMan genotyping assay (ABI, Foster City, CA) in a 25 μl total volume 
of BIORAD CFX 96 in accordance with the manufacturer’s instructions (Licastro F et al., 2010). 
IFN-γ  genes  (+874 T/A, rs2430561)  genotype  was  assayed by RT-PCR using  allele  specific 
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modified  LNA  primers  (TTTATTCTTACAACACAAAATCAAATC+T, 
TTTTATTCTTACAACACAAAATCAAATC+A,  TGTGCCTTCCTGTAGGGTATTATTA).  The 
polymorphic SNP was located at the 3’-position of the forward primers and a single-LNA base  
was incorporated at this position (+) (Proligo, Italy).
RT-PCR was perfprmed in 96 well plates using a BIORAD CFX 96 platform. Reaction volume 
(25 µl), included a SYBR Green PCR Master Mix with the enzyme, Mg2+ and dNTP (ABI, Foster 
City, CA, USA; 200 nmol/L) PCR primers and genomic DNA (0.5 ng/µl). A start of 10 min at  
95°C was followed by 40 cycles at 95°C for 15 s and 60°C for 60 s. (Licastro F et al., 2010).
Detection of EBV DNA
DNA samples were analyzed by qPCR. For the standard curve, we performed a nested PCR with 
an EBV-positive sample under the same conditions as described above. The PCR products were 
loaded  onto  a  2%  agarose  gel  and  purified  with  a  QIA quick  gel  extraction  kit  (Qiagen).  
Concentration of DNA was determined using a Beckman DU 460 spectrophotometer in which the 
purified PCR product was placed onto the apparatus and the optical density (OD) measured (λ = 
260 nm). OD values were converted to the appropriate concentrations (ng/μL). The following 
equation was used to calculate  the  copy numbers  from a known PCR product  concentration: 
weight of PCR fragment (g/μL)/(660 g per mol × number of base pairs of the PCR fragment) × 
(6.023 × 1023) = number of genomic copies/μL (Malorny B et al., 2003). Tenfold dilutions were  
made of this cleaned-up DNA. In each run we added virus-specific standards (102, 103, 104, 105 
copies/5 μL), which were used to generate the reference curve to quantify viral DNA in individual  
samples. Primer  sequences  and  PCR  cycling  conditions  are  listed: 
GCCAGAGGTAAGTGGACTTTAAT, GAGGGGACCCTGAGACGGGT
 (Amplicon size/protein: 96 bp), (PCR cycle conditions: 50 °C: 2 min, 95 °C: 15 min, 45 cycles of 
94 °C: 2 min, 60 °C: 30 s, 72 °C: 30 s, melt curve 65 °C to 95 °C, 4 °C.),  (Limited optical 
Detection: 33 copies/reaction).
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Detection of HHV-6 DNA
DNA samples from peripheral leukocytes were analyzed by qPCR. Standard curve for HHV-6 
was prepared as described above for the EBV standard curve. For the external PCR, 250 ng/5 μL 
of DNA template was added to a 50-μL mixture containing 1 μmol/L of each external primer, 200 
μmol/L of dNTP (Fermentas), reaction Buffer 1X (Euroclone), MgCl2 2 mmol/L (Euroclone), and 
2 U of Thermus aquaticus polymerase (EuroTaq, Euroclone). For the internal PCR, 10 μL of the 
previous PCR reaction was added to a 50-μL mixture under the same conditions as the external  
PCR.  Primer  sequences  and  PCR  cycling  conditions  are  listed: 
TCCATTATTTTGGCCGCATTCGT, 
TGTTAGGATATACCGATGTGCGT (Amplicon size/protein: 173 bp), (PCR cycle conditionsand 
Limited optical Detection as described above for EBV).
Statistical analysis
The different genotypes were statistically analyzed using contingency tables and the chi-square 
(χ2) test, and the odds ratios (OR) and confidence intervals (CI) and their statistical significance 
were also calculated. The level of statistical significance was set at 5%.The mean values of the  
various  quantitative  variables  were  compared  by  means  of  one-way  analysis  of  variance 
(ANOVA) followed by appropriate posthoc comparisons and Bonferroni’s correction. Statistical 
tests were two-sided, and significance was set at p<0.05. 
The Hardy-Weinberg equilibrium was verified for the two control groups. A logistic regression 
model was used to evaluate the effect of several clinical variables and the SNPs on the risk of  
CVD and AMI.
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 RESULTS
Genotype and allele frequency
Table 1shows the SNP numbers, gene positions and mutated alleles of the investigated VEGF, 
ACT, HMGCR, IL-1β, IL-10 and IFN-γ genes, along with the number, mean age and gender of 
the subjects in the different groups. 
Table 1.   SNPs list  and the number,  age and gender distribution of  CTR, Offs,  AMI 
and CMP
Gene polymorphism:
VEGF                       (rs 699947)
IL-10                        (rs 1800896)
IFN-γ                       (rs 2430561)
ACT                         (rs 1884082)
HMG-CR                (rs 3761740 )
IL-1β                       (rs 16944)
SNP at -2578, allele mutation = A
SNP at -1082, allele mutation = A
SNP at +874, allele mutation = A
SNP at -51, allele mutation = T
SNP at -911, allele mutation = A
SNP at -511, allele mutation = T
                          N                                 Mean Age                                              Gender
CTR                321                                   72±5.1                                           158 M/ 163 F
Offs                154                                  55.8±6.7                                             80 M/ 74 F
AMI               267                                 67.7±12.2                                          195 M/ 72 F
CMP              396                                    70±11                                              347 M/90 F
The genotype distribution and allele frequency of the VEGF gene between Offs, AMI and CTR 
groups are shown in Table 2.
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 The CC genotype was more frequent in the Offs than in CTR (63% vs 40.9%, p = 0.0001), and  
also more frequent in the AMI group (65% vs 40.9%, p = 0.0001; OR= 2.689). The percentage of  
VEGF C carriers was significantly higher in the AMI group than in the CTR (95.3% vs 84.5%, p 
= 0.0001; OR = 3.735), whereas the percentage of A carriers was significantly lower in the Offs  
(37.7%, p = 0.0001) and the AMI group (35%, p = 0.0001; OR = 0.373) than the CTR (59.1%). 
The AA genotype was more frequent in the CTR than in the AMI group (15.5% vs 4.7%, p = 
0.0001; OR = 0.269). 
The genotype distribution and allele frequency of the IL-10 gene between Offs, AMI and CTR 
groups are shown in Table 3.
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Table 3 shows the IL-10 genotype distribution and allele frequency in the three groups. The GG 
genotype was more frequent in the CTR than in the Offs (30.5% vs 13%, p = 0.0001) or the AMI 
group (21.1%, p = 0.016; OR = 0.609). The A allele was significantly less frequent in the CTR 
than in the Offs (69% vs 87.7%, p = 0.0001) or the AMI group (78.9%, p = 0.012; OR = 1.674).  
There were also some differences between the Offs and the AMI group: the GG genotype was  
more frequent in the latter (21.1% vs 13%, p = 0.037; OR= 1.795); there was a higher percentage 
of A carriers among the Offs (87.7% vs 78.9%, p = 0.02), in whom the frequency of the AA 
genotype was also higher (35.1% vs AMI =25.7%, p = 0.043). 
Table 4 shows IFN-γ genotype and allele distribution between Offs, AMI and CTR groups. 
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The TT genotype was more frequent in the CTR than in the Offs (30.6% vs 15.7%, p = 0.001), 
whereas the percentage of A carriers was higher among the Offs than the CTR (84.3% vs 69.4%, 
p = 0.001). No difference in the distribution of the IFN-γ polymorphism between the AMI group 
and the CTR was detected, but the frequency of the TT genotype was slightly higher in the AMI 
group than in Offs (24.2% vs 15.7%, p = 0.036; OR= 1.761) and the A allele was less frequent in  
the AMI group than Offs (75.8% vs 84.3%, p = 0.044; OR= 0.584). The SNPs in the promoter  
region  of  the  ACT,  HMGCR  and  IL-1β  genes  were  also  investigated,  but  not  significant 
difference in allele and genotype frequencies between the groups was found (data not shown). 
Association between the triple genotype and cardiovascular risk. 
The concomitant presence of the CC genotype of VEGF, the A allele of IL-10 and the A allele of 
IFN-γ between Offs, AMI and CTR groups (that we called “triple genotype”) was also determined 
and resulted to be associated with an increased risk of AMI, as shown in Table 5. 
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This “triple genotype” was more frequent in the Offs (46.4%) and the AMI (31.8%) than in CTR 
(17.3%), and the differences were highly statistically significant (Offs vs CTR: p = 0.0001, OR = 
4.129; AMI vs CTR: p = 0.0001, OR = 2.224). 
Body mass index (BMI) and blood lipid profile. 
Data regarding BMI and serum lipid profile from Offs, CTR and IMA have been reported in  
Table 6. 
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BMI values  of  Offs  and IMA were  slightly increased  (27  ±  4)  as  compared  with  ideal  age 
matched reference value. Moreover, BMI from our CTR group was higher than Offs and IMA,  
however this difference may be mainly ascribed to the older age of CTR. Lipid profile from the 
Offs population was substantially in  the  normal  range for  their  age cohort.  Once again CTR 
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population showed slightly increased blood levels of total cholesterol, LDL and triglycerides as 
expected according their age range. 
Comparison for BMI, total cholesterol, HDL, LDL, triglycerides and VDL values between Offs 
carriers and non carriers for the triple genotype was performed. The results were display in Table  
7.
As shown in Table 7, no statistical difference for BMI, total cholesterol, HDL, LDL, triglycerides 
and VDL values between Offs carriers and non carriers for the triple genotype was detected. 
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Prevalence of CVE after 24 years of follow up.
The prevalence rates of a history of ischemic heart  disease (AMI or angina pectoris),  stroke, 
ischemic  heart  disease  plus  stroke,  hypertension,  diabetes  and  smoking  in  154  Offs  at  the 
beginning (age 23–35 years; Table 8, panel A) and at the end of the follow up period (age 50– 60 
years; Table 8, panel B) were compared with those of gender and age matched subjects from the 
MONICA Brianza population. 
No difference in the event rates was present between the two populations at the beginning of the 
follow up period. On the contrary, at the end of the follow up the prevalence of ischemic heart  
disease among the male Offs was three times higher, that of stroke was eight times higher, that of  
stroke and ischemic heart disease was three times higher, and that of diabetes was twice as high.  
However, there was no increased prevalence of CVE among female Offs during the same period.
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Detection of EBV and HHV-6 DNA
Data regarding primers, PCR conditions and assay sensitivity for the detection of CMV, EBV, and 
HHV-6 nucleic acid positivity are reported in Table 9.
DNA from CMP, Offs and CTR PBL samples were analyzed by qRT-PCR for the presence of  
HHV6 and EBV. 
In Table 10, data regarding EBV positivity in PBL samples are shown. 
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In all samples, 63.1% of CMP patients, 58.1% of CTR and 47.7% of Offs were positive for EBV 
DNA. No differences between CMP and CTR and between Offs and CTR were found (CMP vs 
CTR  χ2=1.091;  p=0.296;  Offs  vs  CTR  χ2=2.621;  p=0.105).  Instead,  statistically  significant 
differences between CMP and Offs were found (CMP vs Offs χ2=8.460; p=0.004; OR=1.877; CI 
(1.224-2.879)).
A correction for age by a logistic regression analysis between CMP, CTR and Offs was applied 
but  no  statistically significant  differences  were found (CMP vs CTR p=0.952;  CMP vs Offs 
p=0.432; Offs vs CTR p=0.483).
CMP patients were stratified in patients with AMI (CMP AMI) or Angina (aCMP). Data regarding 
EBV positivity in CMP AMI and aCMP, Offs and CTR are shown in Table 11.
39
Among CMP patients, 59.9% of CMP AMI and 65.9% of aCMP were positive for EBV DNA and 
no differences regarding the presence of EBV in CMP group were present. Statistically significant  
differences were observed between aCMP and Offs and CMP AMI and Offs (aCMP  vs Offs: 
χ2=9.927;  p=0.002;  OR=2.117;  CI=1.323-3.388. CMP  AMI  vs  Offs:  χ2=3.936;  p=0.047; 
OR=1.622; CI=1.004-2.618).
EBV positive Offs and CTR subjects were stratified according to the presence of triple genotype 
carriers or not carriers. Data regarding EBV positivity in triple genotype carriers or not carriers  
Offs and CTR are shown in Table 12.
As shown in Table 12, 42.3% of Offs versus 16% of CTR were triple genotype carriers and EBV 
positive  and  the  differences  are  statistically  different  (Offs  vs  CTR:  χ2=10.841;  p=0.001; 
OR=3.850;  CI  (1.684-8.802).  The  presence/absence  of  the  triple  genotype  in  Offs  and  CTR 
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subjects appeared to influence EBV positivity.
In Table 13, data regarding HHV-6 positivity in PBL samples are shown. 
In all samples, 42..4% of CMP patients, 63.6% of CTR and 56% of Offs were positive for HVV-6 
DNA. At first  glance, the HHV-6 positivity seemed to have a correlation with age. A logistic 
regression was applied to correct analysis for age between CMP, CTR and Offs but no statistically 
significant differences were found (CMP vs CTR: Log Reg for Age p=0.312; CMP vs Offs: Log 
Reg for Age  p=0.466; Offs vs CTR: Log Reg for Age  p=0.558).
CMP patients were stratified in AMI patients (CMP AMI) and angina (aCMP). Data regarding 
HHV-6 positivity in CMP AMI and aCMP, Offs and CTR are shown in Table 14.
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Among investigated subjects, 41.2% of CMP AMI patients, 43.3% of aCMP, 63.6% of CTR and 
34.8% of Offs were positive for HVV-6 DNA. No differences regarding the presence of HHV-6 
between the two groups of CMP or between CMP AMI, aCMP, Offs and CTR are present. (CMP 
AMI vs aCMP: χ2=0.172; p=0.678; CMP AMI vs CTR: χ2=10.534; p=0.001; OR=0.405; CI= 
(0.233-0.704); aCMP vs Offs: χ2=2.462; p=0.117; CMP  AMI vs Offs: χ2=1.431; p=0.232; aCMP 
vs CTR: χ2=9.194; p=0.002; OR=0.437; CI=0.255-0.751).
HHV-6 positive Offs and CTR were stratified according to the presence of triple genotype carriers 
or not carriers. Data regarding HHV-6 positivity in triple genotype carriers or not carriers Offs 
and CTR are shown in Table 15.
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In the analyzed groups,  42.6% of Offs and 16.7% of CTR were triple genotype carrier  .The  
presence/absence of the triple  genotype in  Offs and CTR subjects appeared to  affect  HHV-6 
positivity and the  differences  were  statistically different  (Offs  vs  CTR:  χ2=7.656;  p=0.006 ; 
OR=3.704 CI (1.426-9.617)).
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DISCUSSION
The multiple pathogenetic pathways leading to AMI include classical and new risk factors and 
multiple genetic traits  and environmental  factors such as infections microorganisms might  be 
associated with the disease.  Recent  genome-wide association (GWA) studies have contributed 
substantially to the discovery of new SNPs associated with CHD and AMI (Patel RS et al., 2011) 
but  their  clinical  relevance is  still  unclear.  In  fact,  a  single  gene variant  can make a  limited 
contribution to the total genetic load of AMI, and both common and rare gene polymorphisms 
may differentially affect susceptibility to the disease. These factors may also partially explain the 
contradictory results of genetic association studies using the candidate gene approach in AMI 
case/control studies (Kullo IJ et al., 2007; Hamsten A et al., 2008; Chiappelli M et al., 2005).
Familiarity and AMI
Parental history is a widely accepted risk factor for offspring of parents with CVE and AMI,  
although the mechanisms remain unclear.  For instance, Offs with positive parental history for 
CVE (<65 years)  resulted at  higher  risk of  incident  CVE compared with Offs  with negative 
parental history. Despite Offs with positive parental history showed classical risk factors such as 
increased blood pressure, total and high-density lipoprotein cholesterol, CRP levels and decreased 
physical  activity,  less  than  15% of  the  excess  risk was  explained through these risk  factors.  
(Hamer M et al., 2009).
Family history of AMI, stroke, and related risk factors in first-degree relatives was studied. By 
looking  at  the  extent  to  which  parental  history was  associated  with  affected  siblings  within 
disease category. 15.7% cases of acute coronary syndromes occurred in families with ≥2 affected 
first-degree  relatives  compared  with  5.1% strokes.  Therefore,  heritability  of  coronary events 
appeared to be greater than that of cerebral events and AMI was more likely to cluster in families  
than stroke (Banerjee A et al., 2011).
It was recently shown the presence of a relation between a family history of heart attack and the 
occurrence of early AMI in young women. In fact, the rate of AMI among women first-degree 
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relatives  of  AMI cases  was twice  as  high  as  among first-degree relatives  of  controls.  These 
findings suggested that family history of AMI was positively associated with the risk of early 
AMI in women (Friedlander Y et al., 2001). 
It is important to know that subjects with an affected parent have a two-fold greater risk of CHD 
than those without a positive family history (Rumboldt M et al., 2003; Lloyd-Jones DM et al., 
2004; Murabito JM et al., 2005). Genetic studies from children of parents with CVD have shown 
that  genetic  variations  in  the  promoter  region  of  the  APOA1  gene  were  associated  with 
differences in serum ApoA1 and HDL levels in unaffected subjects; this association was also 
influenced by gender and a family history of AMI (Talmud PJ et al., 1994).
A family history and a  still  largely undefined genetic  background greatly influence the early 
clinical  manifestation  of  AMI  and  CVD.  Therefore,  we  investigated  SNPs  in  genes  with  a 
regulatory  effect  on  inflammatory  responses  and  cholesterol  metabolism as  possible  genetic 
markers of an increased risk of CVD in Offs with a positive history of AMI. 
SNPs in the VEGF, IL-10 and IFN-γ genes were differently distributed in Offs and CTR. We 
chose elderly CTR from a longitudinal population study because they did not have a history of 
CVD, and did not experience an AMI or have any other CVD before and during the five years 
follow-up. It is important to note that 45% of the Offs in our investigation had a father who 
suffered an AMI before the age of 56 years. The genetic make-up of the Offs overlapped that of 
the unrelated population of patients with a clinical diagnosis of sporadic AMI (control disease).
Genetic variations and AMI
It has been suggested that the CC genotype of the VEGF gene, together with two other SNPs in 
the promoter region of this gene, increases VEGF gene expression in human myoblasts (Prior SJ 
et al., 2006) and the production of the cognate protein in human peripheral blood lymphocytes 
activated by lipopolisaccaride (Mohammadi M e al., 2009). Therefore, subjects with the VEGF 
CC  genotype  may  produce  increased  levels  of  VEGF  protein  which,  by  deregulating 
angiogenesis, may lead to an increased risk of CVE.
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These data were supported from previously published data regarding the functional relevance of  
IL-10 SNPs. An initial study found that the IL-10 A allele is associated with a two-fold increase in 
transcriptional activity in B cell lines (Rees LE et al., 2002), but it has been subsequently reported 
that the A allele is associated with a reduction in the IL-10 secretion of activated peripheral blood 
lymphocytes (Van der Linde K et al., 2003;  Stanilova SA et al., 2006;  Aborsangaya KB et al., 
2007).
This finding suggest that the suppression of inflammation may be impaired in carriers of the IL-
10 −1082 A allele and that an impaired regulation of inflammatory responses in Offs with one or  
two copies of the IL-10 A allele may increase the risk of CVE.
A decreased release of IFN-γ may negatively affect  the coordination of immune responses in 
vessel walls, accelerate atherogenesis, and increase the risk of CVE in Offs with the IFN-γ A 
allele. Our findings showing an increased frequency of the +874 A allele in Offs are in accordance 
with  another  study reporting  that  patients  with  the  IFN-γ +874 AA genotype  and idiopathic 
dilated cardiomyopathy showed a worse prognosis and an adverse outcome (Adamopoulos S et 
al., 2011). Furthermore, patients with dilated cardiomyopathy showed an impaired activation of 
CD4T cells  by IFN-γ ascribed to a decreased production of this  cytokine (Lindberg E et  al.,  
2010).
The concomitant presence of the CC genotype of the VEGF gene, the A allele of the IL-10 gene,  
and  the  A allele  of  the  IFN-γ  gene  was  more  frequent  in  our  AMI group,  and  significantly 
increased the risk of the disease. It is interesting to note that this triple genotype profile was found 
in 46% of  Offs and led to a presumptive high risk of CVE (OR = 4.129).  This  observation 
supports the notion that Offs with a positive parental history are at high risk of CVE and the pro-
inflammatory genetic signature may be part of the complex genetic background influencing AMI 
risk. Offs were followed up for a 24 years period and the occurrence of CVE registered.
A control group of comparable age from the WHO-MONICA-Brianza study to compare the CVE 
prevalence during the 24 years follow-up of our Offs was also used. 
The  potential  increased  risk  of  CVE  predicted  by  pro-inflammatory  genetic  signature  was 
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partially confirmed by data  from the 24-year  follow-up,  which clearly revealed a  significant 
increase in CVE in Offs. Furthermore, gender and age were conditions with a strong influence on 
CVE, since increased prevalence of CVE was observed only in male Offs (Table 8). The possible 
relationship between the presence of the triple genotype and CVE manifestation in Offs could not 
be  assessed,  since the  limited number  of  Offs  positive  for  CVE.  Further  follow up of  these 
subjects may clarify this topic. 
BMI from Offs was slightly increased when compared with the ideal age value and CTR selected 
for this investigation showed an increased BMI as expected since their advanced age. Cholesterol 
blood profile data from Offs group were in the normal range for their age cohort. Among Offs 
only 33 subjects used for limited time periods statins. Therefore, statins use showed very limited 
influence upon the lipid profile data from Offs population. Furthermore, since the presence of the 
triple genotype/allele signature did not affect BMI or the blood levels of total cholesterol, HDL, 
LDL or triglycerides, we suggest that it might affect the incidence of CVE by mechanisms that  
are partially independent of those affected by the classic risk factors of CVD.
Virus infections and AMI
EBV infects more than 95% of human beings within the first years of life. The virus causes acute  
infections (mononucleosis) in a minority of immune-competent subjects, whereas the majority 
develops  a  lifelong  asymptomatic  infection,  and  the  virus  remains  latent  in  memory  B-
lymphocytes.  EBV is  also  involved  in  the  development  of  several  diseases  such  as  Burkitt 
lymphoma,  Hodgkin  lymphoma,  and  nasopharyngeal  carcinoma  (Kutok  JL  et  al.,  2006). 
Moreover, EBV seems to be involved in the pathogenesis of various neurological diseases, such 
as  encephalitis,  neuritis,  myelitis,  cerebellits,  acute  disseminated  encephalomyelitis,  central  
nervous  system  (CNS)  lymphoma  in  patients  with  human  immunodeficiency  virus  (HIV) 
infection (Kleines M et al., 2011) and multiple sclerosis (Lassmann H et al., 2011). 
HHV-6 is a neurotropic virus and has been associated with multiple neurological diseases and 
disease conditions including seizures, encephalitis, mesial temporal lobe epilepsy, and multiple 
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sclerosis (Yao K et al., 2010). HHV-6 has been found in a higher proportion in AD brain than in  
age-matched controls (Lin WR et al., 2002). 
Evidence for EV, adenovirus, and CMV, parvovirus B19, EBV, HHV-6 association with dilated 
cardiomyopathy has been reported (Pankuweit S et al., 2010; Al-Ghamdi A, 2012). The levels of 
CMV- and EBV- specific  antibodies  were found elevated among patients  with CVD and the 
presence  of  CMV-specific  IgG  was  associated  with  development  of  the  disease.  The 
seroprevalence  of  anti-H.  pylori,  anti-CMV and  anti-HSV-1  antibodies  in  AMI  and  unstable 
angina groups was significantly higher than those of the to control group (Jafarzadeh A 2011).  
Genomic  sequences  of  EBV  and  HHV-8  DNA  in  atherosclerotic  lesion  was  found,  thus 
suggesting  that  the  viruses  could  play  a  role  in  atherogenesis  (Tremolada  S et  al.,  2011; 
Kaklikkaya I et al., 2010). AdV3 and HHV6 sequences coexisted in one case with inflammatory 
cardiomyopathy (Tátrai E et al., 2010).
The seropositivity to CMV, EBV, or HHV-6 in general population is very high. Moreover, we 
were  also  interested  in  the  immune  response  of  the  host  to  infections,  since  with  aging  the 
immune system undergoes significant changes. This process has been called immunosenescence 
and may lead to an increased susceptibility to develop not only infectious diseases but also CVD, 
AD, osteoporosis, autoimmunity, and cancer in elderly (Lang PO et al., 2012).
However, the data regarding seroprevalence and genomic positivity for EBV and HHV-6 viruses 
in  CVD and AMI remain  controversial.  In  fact,  it  is  difficult  to  find  a  linear  association  of 
serological viral positivity with AMI, since of the high seroprevalence in the elderly population. 
Our  investigations  regarding  EBV  and  HHV-6  DNA presence  in  PBL samples  suggest  an 
association of EBV and HHV-6 DNA with CVD and AMI.
In fact, we found that a high proportion of CMP patients had EBV positive blood leukocytes, 
since 63% of CMP, 58% CTR and 47.7% of Offs were EBV positive. Statistically significant  
differences between CMP and Offs were detected. When CMP were stratified in AMI CMP and 
aCMP statistically significant differences remained among AMI CMP, aCMP and Offs. Among 
the analyzed  subjects  42.3% of  Offs  versus  16% of  CTR were triple  genotype  carriers.  The 
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presence of the triple genotype was increased in Offs and this group showed also a high positivity 
for EBV. These findings suggest that the presence of EBV DNA in the PBL might contribute to 
the risk for CVD. EBV positivity was also high in elderly CTR. The immunosenescence process 
of elderly may explain the increased EBV positivity.
A higher proportion of elderly CTR than CMP and Offs was positive for HHV-6 (63.6% vs 42.4 
and 43.8%, respectively). These differences remained when CTR were compared with the two 
subgroups AMI CMP and aCMP. These findings suggest that senescence of immune responses 
might influence both virus subclinical infections and CVD. Whether EBV and HHV-6 persistence 
may independently affect CVD clinical history remains an open question. Between the analyzed 
subjects 42.6% of Offs versus 16.7% of CTR were triple genotype carriers. Offs with the triple 
genotype showed also an increased HHV-6 positivity.
These  findings  showing  an  association  between  elevated  EBV and  HHV-6  DNA positivity,  
suggesting a role of chronic virus infections in CVD by interfering with the efficience of immune 
responses.
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CONCLUSIONS
The concomitant presence of the CC genotype of VEGF, the A allele of IL-10 and the A allele of 
IFN-γ resulted to be associated with an increased risk of AMI and was more frequent among Offs 
with a  positive  parental  history of  AMI.  Therefore,  genetic  variations  impairing the immune 
functions appear to be associated with the pathogenesis of AMI. Inflammatory genes, gender and 
age influence an accelerated aging of cardiovascular system and selected genes with immune 
regulatory functions are part of the complex genetic background contributing to familiarity for 
cardiovascular diseases.
The triple genotype seems to be associated also with the presence of EBV and HHV-6 DNA in 
Offs.
These preliminary results need to be interpreted with caution until they can be replicated in a  
larger  case-control  study.  However,  our  findings  support  the  notion  that  persistent  cycles  of  
latency and reactivation phases  of  these viruses  by stressing the systemic  immune responses 
might induce altered inflammatory processes that, in turn, may accelerate cardiovascular aging 
and  increase  the  prevalence  of  CVD.  Therefore,  EBV  and  HHV-6  might  be  considered 
environmental risk factors for CVD and AMI. Vaccination or antiviral therapy might in the mean 
future decrease the incidence and prevalence of CVD in the elderly.
Further studies are needed to clarify the primary or secondary role of herpes virus infection in 
CVD and AMI. In particular, improved methodology focused on investigating viral latency and 
its effect an immune system might possibly help to better elucidate the role of these pathogens in 
CVD pathogenesis.
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